1. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.

    AIDS Research and Human Retroviruses 32(5):456 (2016) PMID 26559180 PMCID PMC4845681

    Chronic hepatitis C virus (HCV) infection is associated with lower serum concentration of low-density lipoprotein (LDL-C), the primary cholesterol metabolite targeted pharmaceutically to modulate cardiovascular risk. Chronic infection with human immunodeficiency virus (HIV) and treatment with an...
  2. Pneumocystis jirovecii Pneumonia in Human Immunodeficiency Virus Infection.

    Seminars in Respiratory and Critical Care Medicine 37(2):243 (2016) PMID 26974301

    The presentation of Pneumocystis pneumonia (PCP) in previously healthy men having sex with men (MSM) in San Francisco and New York City in 1981 heralded the beginning of the human immunodeficiency virus (HIV) pandemic. Despite a decreasing incidence of PCP among patients with HIV/AIDS (acquired ...
  3. The pharmacist: An indispensable partner in HIV care.

    American Journal of Health-System Pharmacy 73(7):431 (2016) PMID 27001981

  4. High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study.

    Hepatology International 10(2):310 (2016) PMID 26612014 PMCID PMC4778154

    As treatment for chronic hepatitis C (HCV) virus has evolved to all-oral, interferon-free directly acting antiviral (DAA) therapy, the impact of these improvements on patient adherence has not been described. Medication adherence was measured in 60 HCV, genotype-1, treatment-naïve participants e...
  5. Critical Care Medicine After the 2014-2015 Ebola Outbreak: Are We Ready If It Happens Again?

    Critical Care Medicine 44(3):457 (2016) PMID 26901541

  6. Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.

    Clinical Infectious Diseases 62(4):440 (2016) PMID 26503379 PMCID PMC4725378

    Treatment of genotype 1 hepatitis C virus (HCV) infection with combination directly acting antivirals (DAA) for 8-24 weeks is associated with high rates of sustained virologic response (SVR). We previously demonstrated that adding a third DAA to ledipasvir and sofosbuvir (LDV/SOF) can result in ...
  7. Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.

    Clinical Infectious Diseases 62(3):280 (2016) PMID 26521268 PMCID PMC4706633

    The optimal retreatment strategy for chronic hepatitis C virus (HCV) patients who fail directly-acting antiviral agent (DAA)-based treatment is unknown. In this study, we assessed the efficacy and safety of ledipasvir (LDV) and sofosbuvir (SOF) for 12 weeks in HCV genotype-1 (GT-1) patients who ...
  8. Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir.

    AIDS 30(2):261 (2016) PMID 26691547

    As the treatment of hepatitis C virus (HCV) infection has evolved to directly acting antiviral agents, the impact of these directly acting antiviral-only regimens on improving adherence to HCV treatment in HIV/HCV coinfected populations has not been evaluated. The study compared adherence to led...
  9. Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.

    Annals of Internal Medicine 163(12):899 (2015) PMID 26595450

    Treatment of chronic hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) for 6 weeks achieves sustained virologic response (SVR) rates of 95% in some patients. If effective, shorter therapeutic courses could improve adherence and treatment costs. To determine factors predictiv...
  10. Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations.

    Biology of Blood and Marrow Transplantation 21(11):1870 (2015) PMID 26256943

  11. Opportunistic Infections and Mortality: Still Room for Improvement.

    Journal of Infectious Diseases 212(9):1348 (2015) PMID 26044290 PMCID PMC4601919

  12. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.

    The Lancet Infectious Diseases 15(9):1049 (2015) PMID 26187031 PMCID PMC4561573

    Worldwide, although predominantly in low-income countries in the Middle East and Africa, up to 13% of hepatitis C virus (HCV) infections are caused by HCV genotype 4. For patients with HCV genotype 1, the combination of ledipasvir and sofosbuvir has been shown to cure high proportions of patient...
  13. Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.

    Clinical Infectious Diseases 60(12):1743 (2015) PMID 25733369 PMCID PMC4834854

    Hepatitis C virus (HCV) RNA loads serve as predictors of treatment response during interferon-based therapy. We evaluated the predictive ability of HCV RNA levels at end of treatment (EOT) for sustained virologic response (SVR12) during interferon-sparing direct-acting antiviral therapies. HCV g...
  14. Bad bugs, no drugs: are we part of the problem, or leaders in developing solutions?

    Critical Care Medicine 43(6):1153 (2015) PMID 25978153

  15. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.

    The Lancet 385(9973):1107 (2015) PMID 25591505 PMCID PMC4427052

    Direct-acting antiviral drugs have a high cure rate and favourable tolerability for patients with hepatitis C virus (HCV). Shorter courses could improve affordability and adherence. Sofosbuvir and ledipasvir with ribavirin have high efficacy when taken for 8 weeks but not for 6 weeks. We assesse...
  16. Treatment of hepatitis C virus infection.

    Annals of Internal Medicine 162(6):459 (2015) PMID 25775329

  17. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.

    Hepatology 61(3):790 (2015) PMID 25203718 PMCID PMC4340816

    Hepatitis C virus (HCV) modulates intrahepatic cholesterol biosynthetic pathways to promote viral replication. Chronic HCV infection is associated with altered metabolism, including dyslipidemia and insulin resistance (IR), which contributes to disease progression and influences response to ther...
  18. HIV-Related Opportunistic Infections Are Still Relevant in 2015.

    Topics in antiviral medicine 23(3):116 (2015) PMID 26518395

    The incidence of HIV-related opportunistic infections (OIs) has declined in the United States with the increasing use of effective antiretroviral therapy for the treatment of HIV infection. However, the absolute number of patients with OIs remains high and there continues to be considerable asso...
  19. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.

    JAMA 313(12):1232 (2015) PMID 25706232

    There is an unmet need for interferon- and ribavirin-free treatment for chronic hepatitis C virus (HCV) infection in patients co-infected with human immunodeficiency virus (HIV). To evaluate the rates of sustained virologic response (SVR) and adverse events in previously untreated patients with ...
  20. Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.

    PLoS ONE 10(7):e0133236 (2015) PMID 26181438 PMCID PMC4504464

    Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy. Elevated levels of NH2-terminal truncated CXCL10 (3-77aa), produced by DPP4 cleavage, negatively associate with spontaneous clearance of ac...